Harvard Bioscience, Inc. (FRA:HBI)

Harvard Bioscience Statistics

Total Valuation

FRA:HBI has a market cap or net worth of EUR 29.35 million. The enterprise value is 60.29 million.

Market Cap	29.35M
Enterprise Value	60.29M

Important Dates

The next estimated earnings date is Friday, March 6, 2026.

Earnings Date	Mar 6, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	44.58M
Shares Outstanding	n/a
Shares Change (YoY)	+2.01%
Shares Change (QoQ)	+0.57%
Owned by Insiders (%)	7.75%
Owned by Institutions (%)	28.14%
Float	34.30M

Valuation Ratios

PE Ratio	n/a
Forward PE	8.75
PS Ratio	0.39
PB Ratio	2.45
P/TBV Ratio	n/a
P/FCF Ratio	4.63
P/OCF Ratio	4.03
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 9.62, with an EV/FCF ratio of 9.51.

EV / Earnings	-1.31
EV / Sales	0.80
EV / EBITDA	9.62
EV / EBIT	n/a
EV / FCF	9.51

Financial Position

The company has a current ratio of 0.81, with a Debt / Equity ratio of 3.04.

Current Ratio	0.81
Quick Ratio	0.35
Debt / Equity	3.04
Debt / EBITDA	5.87
Debt / FCF	5.75
Interest Coverage	-0.40

Financial Efficiency

Return on equity (ROE) is -135.62% and return on invested capital (ROIC) is -1.02%.

Return on Equity (ROE)	-135.62%
Return on Assets (ROA)	-0.82%
Return on Invested Capital (ROIC)	-1.02%
Return on Capital Employed (ROCE)	-5.80%
Revenue Per Employee	217,103
Profits Per Employee	-133,771
Employee Count	355
Asset Turnover	0.84
Inventory Turnover	1.58

Taxes

In the past 12 months, FRA:HBI has paid 207,109 in taxes.

Income Tax	207,109
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -68.87% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-68.87%
50-Day Moving Average	0.43
200-Day Moving Average	0.43
Relative Strength Index (RSI)	67.80
Average Volume (20 Days)	4,789

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	0.21

Income Statement

In the last 12 months, FRA:HBI had revenue of EUR 74.47 million and -45.88 million in losses. Loss per share was -1.04.

Revenue	74.47M
Gross Profit	42.44M
Operating Income	-1.17M
Pretax Income	-45.68M
Net Income	-45.88M
EBITDA	4.25M
EBIT	-1.17M
Loss Per Share	-1.04

Balance Sheet

The company has 5.81 million in cash and 36.47 million in debt, giving a net cash position of -30.66 million.

Cash & Cash Equivalents	5.81M
Total Debt	36.47M
Net Cash	-30.66M
Net Cash Per Share	n/a
Equity (Book Value)	11.99M
Book Value Per Share	0.27
Working Capital	-9.03M

Cash Flow

In the last 12 months, operating cash flow was 7.29 million and capital expenditures -946,053, giving a free cash flow of 6.34 million.

Operating Cash Flow	7.29M
Capital Expenditures	-946,053
Free Cash Flow	6.34M
FCF Per Share	n/a

Margins

Gross margin is 56.99%, with operating and profit margins of -1.57% and -61.62%.

Gross Margin	56.99%
Operating Margin	-1.57%
Pretax Margin	-61.34%
Profit Margin	-61.62%
EBITDA Margin	5.71%
EBIT Margin	-1.57%
FCF Margin	8.52%

Dividends & Yields

FRA:HBI does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.01%
Shareholder Yield	-2.01%
Earnings Yield	-156.31%
FCF Yield	21.60%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:HBI has an Altman Z-Score of -2.44 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-2.44
Piotroski F-Score	3